Predictive factors for recurrence in patients with Graves’  Disease following treatment with methimazole by Robikhul Ikhsan, Mohammad et al.
J Med Sci, Volume 53, Number 3, 2021 July: 226-231
226*corresponding author: m_robikhul@ugm.ac.id
Journal of the Medical Sciences
(Berkala Ilmu Kedokteran)










Predictive factors for recurrence in patients with Graves’ 
Disease following treatment with methimazole 
Mohammad Robikhul Ikhsan, Raden Bowo Pramono, Hemi Sinorita, Vina Yanti Susanti
Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Public Health, 
and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia
ABSTRACT
Graves’ disease (GD) contributes for 60–80% of all hyperthyroidism. Methimazole 
is the first line drug and most commonly used as antithyroid drug (ATD). However, 
the relapse rate following ATD therapy is 40–50%. The aimed of this study 
was to evaluate long-term ATD treatments and to identify prognostic factors 
that contribute to GD recurrence. A total of 46 GD patients who referred to the 
Endocrinology Clinic, Dr. Sardjito General Hospital, Yogyakarta between January 
2016 and December 2018 with thyrotropin receptor antibody (TRAb) tested and 
treated with methimazole were included in this study. Size of goiter was measured 
based on WHO grading system and eye syndrome based on NOSPEC score system. 
Patients were classified into recurrence and remission groups based on TRAb 
evaluation at 12 month following treatment. Result of thyroid hormone level (FT4) 
and subject characteristic as predictive factors observed at 3-, 6- and 12-month post-
treatment were compared and analyzed. Among 46 patient involved in this study, 23 
patients demonstrated remission of hyperthyroidism based on TRAb evaluation at 
12-month. The size of thyroid at onset of disease in 30 (65%) patients was grade 2 or 
above (p<0.05). Free FT4 levels at the end of observation (12 month) was 1.9±0.6 ng/
dL in recurrent and 1.4±0.5 ng/dL in remission group (p<0.05). TRAb levels at early 
of study was higher in the recurrent group (p<0.05). Logistic regression analysis 
demonstrated that thyroid size, FT4 level, and TRAb at diagnosis were associated 
with recurrencies. In conclusion, GD patients with large thyroids size, high TRAb 
levels, and high FT4 level at the onset of disease tended to fail to respond to ATD and 
were associated with recurrence incidence.
ABSTRAK
Penyakit Graves (Graves Disease/GD) berkontribusi terhadap 60-80% semua 
kejadian hipertiroid. Methimazole adalah obat pilihan pertama dan paling 
sering digunakan sebagai obat antitiroid. Namun, tingkat kekambuhan setelah 
terapi masih tinggi yaitu 40-50%. Tujuan penelitian ini adalah untuk mengkaji 
keberhasilan terapi antitiroid jangka panjang dan mengidentifikasi faktor 
prognostik yang berkontribusi pada kekambuhan GD. Sebanyak 46 pasien GD yang 
dirujuk ke Klinik Endokrinologi - Rumah Sakit Umum Pusat Dr. Sardjito antara 
Januari 2016 dan Desember 2018 dan telah memiliki data pemeriksaan antibodi 
reseptor tirotropin (TSH receptor antibody/TRAb) dan mendapatkan terapi dengan 
methimazole dilibatkan dalam penelitian ini. Ukuran struma diukur berdasarkan 
sistem penilaian WHO dan sindrom mata berdasarkan sistem skor NOSPEC. Pasien 
diklasifikasikan ke dalam kelompok rekuren dan remisi berdasarkan evaluasi TRAb 
pada 12 bulan setelah perawatan. Hasil pemeriksaan dari kadar hormon tiroid (FT4) 
dan karakteristik subjek sebagai faktor prediksi diamati pada 3-, 6- dan 12-bulan 
pasca-pengobatan dan dibandingkan serta dianalisis. Dari 46 pasien yang terlibat 
penelitian, 23 pasien menunjukkan remisi hipertiroidisme berdasarkan evaluasi 
TRAb setelah 12 bulan terapi. Ukuran kelenjar tiroid pada awal timbulnya penyakit 
sebanyak 30(65%) pasien memiliki nilai skor kelas 2 atau lebih (p<0,05). Kadar FT4 
pada akhir pengamatan (12 bulan) adalah 1,9±0,6 ng/dL pada kelompok rekuren 
dan 1,4±0,5 ng/dL pada kelompok remisi (p<0,05). Kadar TRAb pada awal studi 
lebih tinggi pada kelompok rekuren (p<0,05). Analisis regresi logistik menunjukkan 
bahwa ukuran tiroid, kadar FT4, dan TRAb pada saat diagnosis dikaitkan dengan 
kejadian rekurensi. Dapat disimpulkan, pasien GD dengan ukuran kelenjar tiroid 
besar, kadar TRAb tinggi, dan tingkat FT4 yang tinggi pada awal diagnosis penyakit 
cenderung gagal merespons terapi ATD dan dikaitkan dengan kejadian rekurensi.
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INTRODUCTION
Graves’ disease (GD) is   among 
the   most prevalent organ specific 
autoimmune diseases. It is the most 
common cause of hyperthyroidism 
worldwide, about 6080% of all 
thyrotoxicosis cases.1 Graves is an 
autoimmune disease caused by the 
presence of  antibodies called as TRAb 
(TSH receptor antibody) that are active 
against TSH receptors, thus stimulating 
the glands to synthesize and secrete 
thyroid hormones excessively. The 
causes of this disease can be familial 
and associated with other autoimmune 
diseases.2 TRAb examination has 99% 
sensitivity and specificity for Graves’ 
disease. This examination also helps 
diagnose PG in patients with struma 
nodular that appear simultaneously.3
The main mechanism of intratiroidal 
anti-thyroid drugs for inhibition of 
thyroid hormone synthesis competes 
with residues of thyroglobulin tyrosine 
for iodium from thyroid peroxidase 
(TPO)-catalyzed, thus causing a 
decrease amount of mono- and 
diiodotyrosine. In addition, another 
mechanism is to cause a relationship 
disorder between TPO-catalyzed and 
iodotyrosine to synthesis thyroid 
hormones, namely triiodothyronine 
(T3) and tetraiodothyronine (T4).4 The 
antithyroid drug as methimazole (MMI, 
called thiamazole in US) predominantly 
appears to affect B cells and possibly 
accessory cell function. The ability of 
thionamide therapy to directly affect the 
immunological outcomes of GD has been 
supported by previous in vitro and in 
vivo experimental evidence.5
A previous study has revealed that 
MMI dose, pretreatment serum T3 
levels, and goiter size were the major 
determinants of GD patients’ therapeutic 
response to MMI.3 By analyzing the 
factors affecting GD relapse, the 
efficacy of ATD as a treatment for GD, 
and the probability of recurrence of 
GD hyperthyroidism following the 
withdrawal of ATD therapy, therapeutic 
strategies for the treatment of GD may be 
improved.2
The present study was conducted 
to observe the relapse rate of patients 
with GD receiving longterm (12 months) 
treatment with ATD and to evaluate 
the predictive factors that affect the 
recurrence of hyperthyroidism in GD.
MATERIALS AND METHODS
Patients
The present study investigated 
patients with newlydiagnosed GD who 
were referred to the Endocrinology 
Clinic, at Dr. Sardjito General Hospital, 
Yogysakarta, Indonesia. A total of 46 
patients with GD who were referred to the 
Endocrinology Clinic between January 
2016 and December 2018. Patients who 
underwent the TRAb tests and treated 
with methimazole were included in this 
study.
Protocol of study
Following treatment and 
observation, patients were classified 
into remission and recurrent groups 
based on TRAb evaluation at 12 months 
following treatment. Various prognostic 
factors were analyzed and compared, 
including patient age, gender, size of 
thyroid prior to and following treatment, 
thyroid hormone levels, and states of 
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thyrotropin suppression were observed 
at 3-, 6- and 12-month post-treatment.
Diagnosis of GD based on symptoms 
of thyrotoxicosis and elevated free 
thyroxine (FT) 4 levels with low TSH 
and TRAb. The goiter was classified 
into three grades according to the 
World Health Organization (WHO) 
classification of goiter and eye syndrome 
as ophthalmopathy based on NOSPEC 
score system.6,7
All patients were administered 
methimazole daily at a starting dose of 
1030 mg with followup visits at 2-4 weeks, 
followed by once every month and a 
titration regimen for 12 months. Clinical 
presentation and hormone level (FT4, 
TSH) were used to determine the titration 
dose. The TRAb levels and thyroid 
volume were measured at 12month 
intervals. If euthyroidism was achieved, 
which was defined as the elimination 
of the majority of hyperthyroidism 
symptoms and restored serum levels of 
TSH and FT4, pharmacological therapy 
was gradually adjusted and a continued 
dose of MMI was administered in order 
to maintain euthyroidism.
Remission was defined as the state 
when euthyroidism, demonstrated by 
normal ranges of FT4 and TSH levels, was 
achieved following the withdrawal of 
antithyroid drugs for 3 months and TRAb 
levels was converted to normal range. 
Relapse was defined as the state when 
clinical symptom and hyperthyroidism 
was detected at any time following 
treatment with ATD. Recurrence subject 
was defined when hyperthyroidism 
based on clinical symptom and 
laboratory result still occurred following 
the termination of ATD treatment.
A patient record was completed 
for each patient, including age, gender, 
duration of treatment, dose of ATDs 
administered, estimated volume of 
thyroid, relapse of disease status during 
and after treatment, duration of followup 
of serum TSH, FT3, and FT4 levels, 
and TRAb levels at the initiation and 
termination of treatment (12 months).
Statistical analysis
Data were presented as mean ± 
standard deviation (SD) or frequency 
and analyzed using t test or chi square. 
Logistic regression analysis was 
used to evaluate the factors affected 
clinical outcomes. A p value < 0.05 was 
considered significant.
RESULTS
Eleven patients were male and 35 
patients were female. The mean age 
was 42±11 y.o. and the follow-up was 
21±4.8 months. Following long-term 
treatment, 23 subjects demonstrated 
remission of hyperthyroidism based 
on TRAb evaluation at 12-month. The 
average age at diagnosis was 42.6±8.3 
y.o. in the remission group, compared 
with 36.4±8.8 y.o. in recurrence group 
(p<0.05). The thyroid size of grade ≥ 2, 
often in recurrence group 16 (53.4%) 
compared with 14 (46.6%) in remission 
group (p<0.05). TRAb levels at prior 
study were significantly higher in the 
recurrence group compared with the 
remission group (p<0.05).
229
J Med Sci, Volume 53, Number 3, 2021 July: 226-231
TABLE 1. Characteristics of patients with Graves’ disease prior to treatment 







Age (years) 42.6±8.3 36.4±8.8 <0.05*
Gender [n (%)]
•	Men 5 (45.4) 6(54.6) <0.05**
•	Women 18 (51.4) 17(48.5) <0.05**
FT4 (ng/dL)
•	Prior study 4.3±2.2 4.7±1.9 <0.05*
•	3 month 2.1±0.9 2.5±1.1 >0.05*
•	6 month 1.6±0.4 1.7±0.9 >0.05*
•	12 month 1.4±0.5 1.9±0.6 <0.05*
TSHs (µIU/mL) 1.9±1.1 Uncountable 
Eye syndrome [n (%)]
•	Yes 10 (55.5) 8(44.5)
>0.05**
•	No 13 (46.4) 15 (53.6)
Size of goiter  [n (%)]
•	Grade I 9 (56.2) 7 (43.8)
<0.05**
•	Grade II and above 14 (46.6) 16 (53.4)
TRAb (U/l)
•	0 month 19.2±11.3 32.6±12.2 0.001*
•	12 month 1.1±0.5 19.4±5.3
Mean daily doses of MMI 
treatment (mg/day)
•	0 month 25.3±12.3 28.6±1.7 >0.05*
•	3 month 18.2±7.5 24.5±11.3 <0.05*
•	6 month 12.7±4.8 22.1±8.6 <0.05*
•	12 month 2.1±0.3 11.4±5.3 <0.05*
Eye syndrome was defined by a NOSPECS score ≥2; FT: free thyroxine; sTSH: 
sensitive thyroid stimulating hormone; TRAb: thyrotrophin receptor antibody; 
*) analyzed with t test; **) analyzed with chi square.
Logistic regression analysis 
demonstrated that the following factors 
significantly affected clinical outcomes 
between remission and recurrence 
i.e. thyroid size [OR=8.725; 95%CI= 
4.10330.519; p=0.001]; TRAb level 
(OR=1.712; 95% CI=1.0422.116; p=0.001); 
and the FT4 level (OR=1.629; 95% 
CI=1.1042.654; p=0.023).
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TABLE 2. Logistic regression analysis that affected disease 
outcomes
Variable OR 95% CI p
Age 1.02 0.726-1.255 0.135 
Gender 0.89 0.913-1.478 0.085
Dose of treatment 1.14 0.682-1.792 0.213
Thyroid size 8.72 4.10330.519 0.001
TRAb level 1.71 1.0422.116 0.001
FT4 level 1.62 1.1042.654 0.023
and others providing care for patients 
with this condition. Methods: The 
American Thyroid Association (ATA 
(ETA),11 the standard duration of 
antithyroid therapy in GD ranges from 
12-18 months. The rate to relapse and 
incidence of hyperthyroidism after the 
duration of therapy ranges from 30 to 
70%. The relapse rate was high in those 
with positive TRAb at the time of drug 
withdrawal although the level of thyroid 
hormones were normal.12
The duration of therapy that 
is necessary for patients with GD 
remains unclear.13 Previous studies 
have demonstrated that treatment 
durations of >18 months were not able to 
improve remission rates.14 Furthermore, 
Quadbeck et al.15 demonstrated that 
TSH suppression at the time of drug 
withdrawal was a predicting factor for 
the recurrence of GD. In the present study, 
the number of patients with normal 
TSHs level was still low in the recurrence 
group, as compared with the remission 
group at 3, 6 and 12 months following 
ATD treatments when euthyroidism was 
achieved.
CONCLUSION
In conclusion, patients with large 
thyroids size, high level of FT4 and TRAb 
following treatment with ATD experience 
recurrence. Therefore, the results of the 
present study suggested that GD patients 
with the above characteristics should be 
provided alternative treatment.
DISCUSSION
The use of antithyroid drug (ATD) 
as methimazole treatment remains the 
primary method of management for 
GD induced hyperthyroidism in various 
countries. However, the relapse rate is 
high following the termination of ATD 
treatment.5 ATD prognosis factors have 
previously been studied however, unified 
classification criteria for the prognosis of 
treated hyperthyroidism for remission, 
cure, drug withdrawal, and recurrence 
is yet to be established worldwide.8
Graves disease is an organ specific 
autoimmune disease of the thyroid 
caused by TRAb directing against the 
TSH receptor in the thyroid follicular 
cells. Treatment outcomes of ATD 
administration may be predicted 
trough TRAb levels at the time of drug 
withdrawal. In the present study, a 
number of patients with GD achieved 
a longterm remission following ATD 
therapy, which may be a result of the 
direct immunosuppressive action of 
ATDs.9 
Based on guidelines from the 
American Thyroid Association 
(ATA)10 and the European Thyroid 
Associationmanifestations, and potential 
therapies. Appropriate treatment 
requires an accurate diagnosis and 
is influenced by coexisting medical 
conditions and patient preference. This 
document describes evidence-based 
clinical guidelines for the management 
of thyrotoxicosis that would be useful to 
generalist and subspecialty physicians 
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